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Background/aim: In this study, the efficiency of using low-dose hepatitis B immunoglobulin (HBIG) plus antiviral treatment according
to individual needs has been evaluated in posttransplant hepatitis B virus (HBV) patients.
Materials and methods: We retrospectively evaluated 179 patients who were admitted between 2009 and 2014. Five thousand IU
intravenous HBIG was given in the anhepatic phase, and 400 IU/day intramuscular (IM) HBIG was given in the posttransplant period.
After HBsAg seroconversion, 400 IU IM HBIG was continued as prophylaxis every two weeks.
Results: The average follow-up period was 26 (2–65) months. Seventy patients had hepatocellular carcinoma (HCC). The HBV
recurrence was 4.5% in the first year, and 5.8% in the third year. The HBsAg became negative in 11 (2–63) days, and anti-HBs became
positive in 9 (1–31) days. HBsAg positivity occurred in 6 patients during the follow-up period. Five of these patients were those who
underwent transplantation due to HCC. In 5 of the HCC patients, in whom HBsAg became positive, tumor recurrence was observed
after 0.3–9.9 months. HBsAg positivity was more frequently detected in patients with HCC (P = 0.009).
Conclusion: The HBV recurrence should be evaluated as a predictor of the HCC recurrence in patients who were transplanted due to
HCC.
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1. Introduction
Prophylactic hepatitis B immunoglobulin (HBIG) in
combination with oral antiviral therapy has become
a standard treatment for patients who undergo liver
transplantation surgery due to Hepatitis B [1–3]. One of
the most important factors affecting posttransplant costs
is the amount of consumed HBIG [1–3]. HBIG reduces
the number of virions within the circulation and ensures
the lysis of infected hepatocytes. However, escape and
surface mutants may sometimes develop in the course of
treatment. Oral antivirals, on the other hand, inhibit the
reinfection of hepatocytes as well as the replication of the
mutant virions that have developed. Thus, the combination
therapy generates a synergistic effect [4]. There are HBIG
regimens used in different ways [5–9] as follows; 1) In
anhepatic phase, HBIG is administered intravenously (IV)
as 4000–10,000 IU/mL [10]. 2) For the initial 3–7 days
after the liver transplantation, 2000 to 10,000 IU HBIG
a day is administered in an intramuscular or intravenous
way. 3) In order to ensure the maintenance of anti-HBs

> 100 IU/L after the transplantation, either a high-dosage
medication is administered as 10,000 IU of HBIG with a 4
week-cycle or a low-dosage medication is administered as
400–2000 IU of HBIG with a 2-week cycle [11,12].
In various studies, it was seen that HBIG used in low
doses could be as effective as high doses. In different
studies, it was shown that 1- to 2-year HBV recurrence
for HBIG 400–800 IU with a maintenance dose applied
intramuscularly every two weeks proved to be below 10%
[13–15].
In this study, we aimed to investigate the efficiency of
low-dose HBIG plus nucleos(t)ide analogs and the factors
affecting hepatitis B recurrence in patients who underwent
liver transplantation due to hepatitis B.
2. Materials and methods
We retrospectively evaluated a cohort of 179 (154 M/25
F) patients from the liver transplantation center who
underwent liver transplantation due to Hepatitis B-related
decompensated cirrhosis and hepatocellular carcinoma

* Correspondence: sezginvatansever19@gmail.com

This work is licensed under a Creative Commons Attribution 4.0 International License.

1019

VATANSEVER et al. / Turk J Med Sci
(HCC) between July 2009 and February 2014. The mean
age of the patients was 51.8 ± 9.6 (15–71) years.
Research involving human subjects (including human
material or human data) that is reported in the manuscript
is in compliance with the Helsinki Declaration. This study
was approved by the Ethical Committee.
2.1. Immunosuppressive regimen
A total of 500 mg methylprednisolone was administered on
the day of operation. Starting from the first postoperative
day, a daily dose of 100 mg was administered. The dose was
reduced by 10 mg each day until it reached a minimum
daily dose of 20 mg. This dose of 20 mg/day was given for
a month, and then was decreased by 5 mg every month.
After 4–6 months, prednisolone was discontinued. On
the first postoperative day, 1 mg tacrolimus 2 × 1 po was
administered, and the dose was augmented to maintain a
blood level of 5–15 ng/mL; 15 ng/mL to begin with and 5
ng/mL to reach at the end of the first year and afterwards.
On the other hand, sirolimus or everolimus was started
in the patients who had an increase of creatinine level or
in whom specific side effects developed against tacrolimus.
Mycophenolate mofetil (MMF) was also added for the
patients for whom immunosuppressive therapy remained
insufficient. Each patient was given oral antiviral treatment
(Lamivudine (LAM), Adefovir (ADV), Entecavir (ENT),
Tenofovir (TDF), Telbivudine (LdT)) in the pretransplant
period. HBV-DNA levels became negative after oral
antiviral treatment prior to transplantation in all of the
patients. The preoperative oral antiviral treatment was also
continued postoperatively for all patients.
2.2. HBV reactivation prevention strategy
The patients were administered 5000 IU IV HBIG in
the anhepatic phase. During the posttransplant period,
HBIG was continued at 400 IU IM daily. HBsAg and
anti-HBs status was examined 3 days a week (Monday,
Wednesday, and Friday). After HBsAg became negative
(HBsAg < 1.0 S/CO (Negative)) and anti-HBs (anti-HBs
> 10 IU/L (positive)) became positive, the daily HBIG
administration was changed to HBIG 400 IU IM once
every 2 weeks. HBsAg status was studied through the
use of ARCHITECT HBsAg Qualitative II device. After
HBsAg became negative, it was followed up at the intervals
of 3–6 months. The HBV recurrence was accepted as the
positivity of HBsAg with/without detectable serum HBVDNA.
Anti-hepatitis C virus (HCV) positivity was confirmed
by HCV-RNA using real-time PCR.
2.3. Statistical analysis
In the analysis of the relevant data, the SPSS 17.0 Statistics
Program (SPSS Inc., Chicago, IL) was used. All of the
digital values are given as mean value ± standard deviation
or in the median form. The chi-square test was used for
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the categorical variables. In addition, the normality of the
groups, as well as their compliance with homogeneity,
was evaluated. The data incompatible with the normal
distribution were evaluated using the Mann–Whitney
U test, whereas those compatible with the normal
distribution were evaluated using Student’s t-test. The
Kaplan–Meier method was used to estimate the survival
curves. The survival curves were compared across the
ordered categories with the Log-Rank test for trend. The
relationship between the dependent and independent
variables was investigated through regression correlation
analysis. P < 0.05 was accepted statistically significant.
3. Results
The demographic data and the characteristics of the study
group are shown in Table 1. The mean follow-up period
was 26 (2–65) months. The HBsAg measurements of all
the patients were positive at the time of the transplantation
operation. The mean HBIG used by the patients was 20,885
± 2898 IU in the first year, 30,718 ± 2366 IU in the second
year, and 42,362 ± 3028 IU in the third year. With the use
of our HBIG treatment regimen, the anti-HBs titration in
17 (9.5%) patients did not exceed 100 IU/L.
HBsAg recurrence occurred in 6 patients within 16.1
months (Table 2). The HBV recurrence was determined to
be 4.5% in the first year, 5.8% in the second year, and 5.8%
in the third year.
In one patient in whom anti-HBs titration did not
exceed 100 IU/L, HBV recurrence occurred. This patient
had no diagnosis of HCC.
Thirty-three of the transplant patients (18.4%)
received an organ from a cadaver whereas 146 patients
received an organ from a living donor. HCC was
diagnosed in 70 of the patients. Of these patients, 15
were incidentally detected in the explant liver. Thirty
of the patients (42.8%) with HCC were those that had
exceeded the Milan Criteria (a single tumor ≤5 cm
or a maximum of 3 total tumors with none >3 cm).
Four patients (2.2%) had HCV coinfection and 56 patients
(35.2%) had HDV coinfection. HCV-RNA levels varied
between 104 and 106 IU/mL in the patients with HCV.
HBV recurrence was not observed in these patients.
Of 6 patients with HBV recurrence, 5 had been
transplanted due to HCC. During the follow-up period,
14 patients developed HCC recurrence and 5 (35.7%)
of them had HBsAg recurrence before HCC recurrence.
Thirteen of these patients who developed HCC recurrence
exceeded the Milan Criteria. In addition, all the patients
who had HBsAg recurrence exceeded the Milan Criteria.
Prominent HBsAg positivity was detected more frequently
in patients with HCC than without HCC (P = 0.009)
(Figure). With the Cox regression multivariate analysis,
HBV recurrence was determined to be associated with the
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Table 1. Characteristics of the patients.
Total
n = 179

HCC
n = 70

non-HCC
n = 109

P-value*

Age

51.8 ± 9.6

56.2 ± 7.7

48.8 ± 9.6

<0.001

Sex (F/M)

25/154

5/65

20/89

0.046

Follow-up period (months)

26 (2–65)

20 (2–63)

27 (2–65)

0.016

MELD

14 (6–35)

10 (6–29)

16 (6–35)

<0.001

CHILD

8 (5–15)

7 (5–13)

9 (5–15)

<0.001

Weight of patients (kg)

78 ± 14

78 ± 15

77 ± 13

0.267

Weight of graft (gr)

788 ± 151

760 ± 147

803 ± 151

0.097

Weight of explant liver (gr)

1180 ± 320

1273 ± 340

1115 ± 292

0.001

Cadaver/living donor

33/146

16/54

17/92

0.241

Log HBV-DNA before treatment

5.3 ± 1.6

5.4 ± 1.5

5.0 ± 1.6

0.233

HBeAg

15 (8.4%)

7 (10%)

8 (7.3%)

0.725

Anti-Delta

56 (31.2%)

11 (15.7%)

45 (41.3%)

0.001

HBs Ag negativity (days)

11 (2–63)

10 (2–63)

11 (2–41)

0.777

Anti-HBs positivity (days)

9 (1–31)

8.5 (2–24)

9 (1–31)

0.982

Anti-HBs > 100 IU/ml (days)

10 (2–60)

10 (2–32)

11 (2–60)

0.546

Antiviral (TDF/ENT)

63 (35.2%)

24 (34.3%)

39 (35.8%)

0.879

Antiviral (LAM/ADV/LdT)

116 (64.8%)

46 (65.7%)

70 (64.2%)

0.901

*Comparison of the patients with HCC and non-HCC.
Table 2. The characteristics of the patients in whom HBV recurrence has occurred.
Age

Sex

Etiology

Antiviral
drug

HCC
existence

HBV recurrence
(months)

HCC recurrence
(months)

Outcome
(months)

55

Male

HBV-HDV

LAM

Yes

3.5

10.1

14 (died)

61

Male

HBV

LAM

Yes

5

13

15 (died)

52

Male

HBV

ENT

Yes

6.1

6.4

7.3 (died)

46

Male

HBV-HDV

LAM

No

10.4

-

64 (alive)

62

Male

HBV

ADE+LAM

Yes

10.5

20

34 (died)

62

Male

HBV

TEN

Yes

16.1

26

45 (died)

presence of HCC prior to LT (OR = 10.17; 95% CI: 1.18–
87.14; P = 0.034). HBV recurrence occurred in 2 patients
with HDV hepatitis. The HDV was not effective on HBV
recurrence in liver transplanted patients (OR = 0.406; 95%
CI: 0.42–3.90; P = 0.435).
None of the patients died because of liver failure due
to HBV recurrence. An elevation of liver enzyme due to
recurrence occurred in 1 patient. The antiviral treatment
of this patient was replaced with the potent antiviral agent
(TDF).
Sixty-three patients were given a potent antiviral agent.
HBV recurrence developed in 2 of these patients. There

was no significant difference between patients who were
given potent (TDF/ENT) and nonpotent antiviral agent
(OR = 0.962; 95% CI: 0.16–5.76; P = 0.967).
No relationship was determined among patients’
weight along with the HBsAg negativity (P = 0.221, r =
0.056), anti-HBs positivity (P = 0.599, r = 0.013), and the
anti-HBs that were >100 IU/L (P = 0.708, r = –0.042).
4. Discussion
Hepatitis B is still the most common cause of liver
transplantation in developing countries [16]. Although
different treatments and HBIG practices have been

1021

VATANSEVER et al. / Turk J Med Sci

Figure. HBV recurrence of the patients with HCC and without HCC.

developed throughout the years, there is still no standard
treatment protocol to prevent postoperative recurrence.
The HBIG applied during our study period was seen
to have ensured HBsAg negativity as much as the other
regimens [13–15]. The total HBIG dose used in our study
is lower than the low dose of HBIG applied in other
previous studies [3,17–19].
In a study conducted by Jiang et al., which comprised
233 patients and also included an average 31-month
follow-up period, an average of 23,000 IU HBIG was used
in the first year, whereas in the second year, 34,000 IU
HBIG was used. Recurrence was identified in 14 (6.2%)
patients [20].
On the other hand, in another low-dose protocol
referred to as the Australasian Protocol, <10% recurrence
took place in those who used 15,000 IU HBIG in the first
year and those who used 25,000 IU HBIG in the second
year [8,21].
In another study in which 114 patients received a lowdose HBIG, 2000 IU HBIG was used in the anhepatic
phase, 800 IU HBIG was used monthly in maintenance,
and thus, a cumulative of 18,000 IU HBIG was used in
the first year. During the 20-month follow-up period,
recurrence was seen in 16 patients. The recurrence was
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determined to be as high as 13.5% in the first year and
15.2% in the second year [22]. In addition to that, the rate
of HBV recurrence was reported to be 1%, 3%, and 3% at
1, 3, and 5 years respectively with low-dose of HBIG plus
antiviral treatment in our region and HCC recurrence was
reported as a risk factor for HBV recurrence (HR: 12.3, P
= 0.02) [23].
In our study, we determined that HBV recurrence was
lower than that in other studies that utilized a low-dose
HBIG regimen. This finding may be due to lower HBeAg
positivity, lower HBV-DNA levels, higher HDV coinfection rate, and more frequent use of potent antivirals
in the pretransplantation period in our patients [15,24–
27]. Another factor was the unlimited administration of
HBIG until HBsAg became negative, not depending on a
given period specified by the protocol.
In our study, while the day that HBsAg became negative
was 11 (2–63), the anti-HBs positivity was observed on day
9 (1–31). The time when anti-HBs reached above 100 IU/L
corresponds to the same period when HBsAg became
negative, such as 10 (2–60) days. As is also recommended
in several studies, the goal to raise anti-HBs above 100 IU/L
ensures long-term HBsAg negativity [28]. It was observed
that 90.5% of anti-HBs titration reached above 100 IU/L.
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No HBsAg positivity occurred in any of the patients whose
anti-HBs were over 100 IU/mL and who had no HCC.
HBsAg reactivation occurred only in 1 (0.9%) of the
patients without HCC. This patient’s anti-HBs did not
rise above 100 IU/L. In a study where a similar amount
of HBIG was used yearly in patients without HCC, HBV
recurrence occurred at a rate of 2.3% in the first year and
6.2% in the third year [20].
The most striking finding in our study is the fact
that HBV recurrence is higher in the patients with HCC
(8.1% and 0.9%) (P = 0.009). However, in our study, the
recurrence in both of the groups was lower when compared
with the former studies.
On the other hand, in a study conducted by Kıyıcı
et al., HBV recurrence in patients with HCC during the
31-month follow-up period was determined to be higher
in comparison to those without HCC (23.6% and 5.5%,
respectively) [18]. Similarly, in a study conducted by Faria
et al., HBV recurrence was higher in those with HCC
during the 15-month follow-up period (35.5% and 4.4%)
(P < 0.0001) [29].

Faria et al. showed that there was cccDNA in both HCC
cells and in nontumor cells in the explanted livers from the
patients who had recurrent HCC, which suggested that
the HBV replication might also appear in tumor cells [29].
Since the proliferation ability of immortal tumor cells is
rather high, the replication is also high, indicated by the
presence of HBsAg within the blood [30,31]. Thus, in
this study, it was observed that HCC recurrence appeared
0.3–9.9 months after HBsAg became positive and HBV
recurrence should be evaluated as a predictor of HCC
recurrence.
The primary restriction of our study is that by lowering
the dose of HBIG more and more, the optimum amount
of HBIG usage could not be investigated. In addition, the
antiviral treatment was not homogeneous and we did not
study HBV-DNA polymerase gene mutation in patients
with HBV recurrence.
In conclusion, low-dose HBIG plus antiviral treatment
is effective in prevention of HBV recurrence after liver
transplantation and HBV recurrence is a predictor of HCC
recurrence after liver transplantation.
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